NCT02063360 is a Phase 1 clinical trial of BMS-663068 in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare.

Who is sponsoring NCT02063360?

NCT02063360 is sponsored by ViiV Healthcare.

What drugs are being tested in NCT02063360?

Interventions in NCT02063360: BMS-663068, Darunavir (DRV), Ritonavir (RTV), Etravirine (ETR).

What condition does NCT02063360 study?

NCT02063360 studies Infection, Human Immunodeficiency Virus.

Is NCT02063360 still recruiting?

NCT02063360 is currently completed. Last updated 8 August 2017.

Last reviewed 2017-08-08 · How we verify

NCT02063360

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Completed Phase 1 Last updated 8 August 2017

What this trial tests

Phase 1 trial testing BMS-663068 in Infection, Human Immunodeficiency Virus in 42 participants. Completed in 13 May 2014.

Timeline

1 February 2014

Primary endpoint
1 May 2014

13 May 2014

Quick facts

Lead sponsor	ViiV Healthcare
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	42
Start date	1 February 2014
Primary completion	1 May 2014
Estimated completion	13 May 2014

Drugs / interventions tested

BMS-663068 — full drug profile →
Darunavir (DRV) — full drug profile →
Ritonavir (RTV) — full drug profile →
Etravirine (ETR) — full drug profile →

Conditions studied

Infection, Human Immunodeficiency Virus — all drugs for Infection, Human Immunodeficiency Virus →

Sponsor

ViiV Healthcare — full company profile →

Who can join

Adults 18 to 50, any sex, with Infection, Human Immunodeficiency Virus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if there is an interaction in healthy subjects taking BMS-663068 with Darunavir/Ritonavir and/or Etravirine.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
Moore K, Thakkar N, Magee M, Sevinsky H, et al · · 2022 · cited 9× · PMID 35315687 · DOI 10.1128/aac.02251-21

Verify or expand the search:

Other trials of BMS-663068

Trials testing the same drug.

NCT02805556 — Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing · Phase 1 · completed
NCT02666053 — A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release For · Phase 1 · completed
NCT02666001 — A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone · Phase 1 · completed
NCT02508064 — Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Pro · Phase 1 · completed
NCT02480894 — A Open-label, Drug-Drug Interaction With Maraviroc (DDI) · Phase 1 · completed

Other recruiting trials for Infection, Human Immunodeficiency Virus

Currently open trials in the same condition.

NCT02951052 — Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpiv · Phase 3 · active not recruiting

Other ViiV Healthcare trials

Trials by the same sponsor.

NCT07393659 — A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative · Phase 3 · not yet recruiting
NCT07525544 — A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants · Phase 1 · not yet recruiting
NCT07275606 — A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1 · Phase 1, PHASE2 · not yet recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT07053384 — A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Vir · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02063360 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ViiV Healthcare
Last refreshed: 8 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02063360.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing